Skip to main content

Bruker Daltonics, AXS Posts Q2 Revenue, R&D Growth

NEW YORK, Aug. 7 (GenomeWeb News) - Bruker Biosciences' Daltonics division saw its second-quarter revenue grow more than 23 percent year over year, and its Bruker AXS unit grew more than 10 percent. Bruker Daltonics and Bruker AXS merged last month to form Bruker Biosciences.

 

Total revenue at the Daltonics division for the period ended June 30 grew to $34.4 million from $28 million in the same quarter one year ago. Receipts for the AXS unit, meantime, increased to $26.5 million from $24 million year over year.

 

R&D spending in the quarter for the Daltonics units inched up to $6.6 million from $5.1 million during the same period last year, and also increased to $3.2 million from $2.8 million for the ASX division, Bruker said.

 

As a result, Bruker Daltonics in the current second quarter posted a net loss of $200,000, or $0 per share, down from $4.2 million, or $.08 per share, in the year-ago period. Bruker AXS, meantime, reported net losses of $2 million, or $.03 per share, up from $600,000, or $.01 per share, year over year.

 

Bruker Daltonics said it had around $46.8 million in cash and short-term investments as of June 30, and Bruker AXS said it had roughly $48 million through the same period.

 

Click here for more information.

 

 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.